NUVB -- SPAC offering February, 2021

SANA -- initial public offering February, 2021

BEAM -- initial public offering February, 2020

LYEL -- initial public offering June, 2021

Acquired by Bayer -- August, 2021

Developing novel therapeutics using precision medicine approaches to neuroscience drug development

Bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics

Developing defined complex microbial communities to provide a robust and lasting cure for high unmet need diseases

A cellular immunotherapy company creating a hybrid platform that integrates innate and adaptive programs to eliminate disease